{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 56,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/9",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.09,
        "y": 0.69
      },
      "kind": "image",
      "text": "Novartis, Pfizer, Lilly, Pierre Fabre logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d204ab43-6f05-4e12-9652-b918c5a85cdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.45,
        "y": 0.655
      },
      "kind": "paragraph",
      "text": "Active CTCSAs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b0e1618-66c5-466b-9af5-cabe2ab08733",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "4 Further enrollment gated on readouts from other sub-studies. CTCSA: clinical trial collaboration and supply agreement",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ce82e0b-8efb-48e0-8aaa-05caf3291be6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.165
      },
      "kind": "table",
      "text": "Indication, Benchmark, Regimen tested, Erasca trial(s) for 7 columns of clinical data",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c1ec6e6-0f5d-4dfe-afd3-4d4f58e5ea69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Erasca's clinical development plan generates multiple ways to win for patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8d7f1a3-f810-4f5b-b609-9278075d1e78",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "4fc89fa5-1a3c-44b2-98ad-f360065331a6",
      "evidence": "Erasca's clinical development plan generates multiple ways to win for patients",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "3458a351-459a-451e-829e-a581eb572b30",
      "evidence": "The slide presents a structured comparison of clinical indications, benchmarks, and trial regimens.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 6,
      "beatId": "dba801b5-a4b0-4e64-a12d-ace71b366d55",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Challenges in current cancer treatment and unmet needs",
      "beatSlug": "rags-to-riches-early-struggles",
      "evidence": "Slides 6-15 discuss current treatment limitations and unmet needs in cancer",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "35467dbb-a048-4577-a17f-95d4c07fd9a3",
      "evidence": "Slides 5-10 introduce the pathway and pipeline",
      "position": 0,
      "objective": "Introduce RAS/MAPK pathway and Erasca's pipeline",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}